Novaliq GmbH-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Novaliq GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013966
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Novaliq GmbH (Novaliq) is a drug delivery company that develops pharmaceutical formulations. The company develops novel ophthalmic and dermatological products, and solutions for organ preservation based on the physicochemical properties of semifluorinated alkanes. It offers NovaTears, a preservative free eye drop product for the relief of discomfort under dry eye syndrome. Novaliq also has products in pipeline for the treatment of glaucoma and other retinal diseases. The company offers its SFA technology as a delivery platform for external co-development cooperations. It licenses its SFA technology to distribution partners who completes registration studies. Novaliq is headquartered in Heidelberg, Germany.

Novaliq GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Novaliq GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Novaliq GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Novaliq Raises US$18 Million In Venture Financing 10
Novaliq Raises US$5.2 Million In Venture Financing 11
Novaliq Secures US$3.32 Million In Venture Financing 12
Partnerships 13
Novaliq Enters into Partnership with University of Cologne 13
Licensing Agreements 14
AFT Pharma Enters into Licensing Agreement with Novaliq 14
URSAPHARM Enters into Licensing Agreement with Novaliq 15
Novaliq GmbH – Key Competitors 16
Novaliq GmbH – Key Employees 17
Novaliq GmbH – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Jun 27, 2017: NOVALIQ Strengthens Executive Management Team with the Appointment of Gabriela Burian, MD, MPH, as Chief Medical Officer 19
Oct 06, 2016: Novaliq Strengthens Executive Management Team by Appointing Christian Roesky, PhD, as Chief Executive Officer 20
Clinical Trials 21
Jan 05, 2017: Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol in Adults with Moderate to Severe Dry Eye Disease 21
May 05, 2016: Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease 22
Feb 16, 2016: Novaliq Begins Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Novaliq GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Novaliq GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Novaliq GmbH, Deals By Therapy Area, 2011 to YTD 2017 8
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Novaliq Raises US$18 Million In Venture Financing 10
Novaliq Raises US$5.2 Million In Venture Financing 11
Novaliq Secures US$3.32 Million In Venture Financing 12
Novaliq Enters into Partnership with University of Cologne 13
AFT Pharma Enters into Licensing Agreement with Novaliq 14
URSAPHARM Enters into Licensing Agreement with Novaliq 15
Novaliq GmbH, Key Competitors 16
Novaliq GmbH, Key Employees 17

★海外企業調査レポート[Novaliq GmbH-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ICF International, Inc.:企業の戦略・SWOT・財務情報
    ICF International, Inc. - Strategy, SWOT and Corporate Finance Report Summary ICF International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Southwestern Electric Power Co:企業の戦略的SWOT分析
    Southwestern Electric Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Tuesday Morning Corporation:企業の戦略・SWOT・財務情報
    Tuesday Morning Corporation - Strategy, SWOT and Corporate Finance Report Summary Tuesday Morning Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Nissin Electric Co Ltd (6641):企業の財務・戦略的SWOT分析
    Nissin Electric Co Ltd (6641) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • DEME NV:電力:M&Aディール及び事業提携情報
    Summary DEME N.V. (DEME), a subsidiary of Compagnie d'Entreprises CFE SA is a dredging and hydraulic engineering services company. The company offers services, which include engineering solutions, installation of offshore wind farms, services to oil and gas companies, environmental activities such a …
  • Crescendo Bioscience Inc-医療機器分野:企業M&A・提携分析
    Summary Crescendo Bioscience Inc (Crescendo), a subsidiary of Myriad Genetics Inc is a molecular diagnostics company that concentrates on rheumatology. The company develops quantitative, objective, and biology based tests for rheumatologists. Its vectra DA is an advanced blood test for rheumatoid ar …
  • H.B. Fuller Co (FUL):企業の財務・戦略的SWOT分析
    H.B. Fuller Co (FUL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Juhl Energy Inc:企業の戦略的SWOT分析
    Juhl Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Best Buy Co, Inc.:企業の戦略・SWOT・財務情報
    Best Buy Co, Inc. - Strategy, SWOT and Corporate Finance Report Summary Best Buy Co, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • SHL TeleMedicine Ltd (SHLTN):企業の財務・戦略的SWOT分析
    SHL TeleMedicine Ltd (SHLTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Berkshire Hathaway Energy Co-エネルギー分野:企業M&A・提携分析
    Summary Berkshire Hathaway Energy Company (BHE), a subsidiary of Berkshire Hathaway Inc., generates, transmits, stores, distributes, and supplies electricity; and procures, transports, distributes and sells natural gas through its subsidiaries. It generates power through diversified energy sources s …
  • AMAG Pharmaceuticals Inc (AMAG):医療機器:M&Aディール及び事業提携情報
    Summary AMAG Pharmaceuticals Inc (AMAG) develops and commercializes specialty pharmaceutical products with focus on maternal health, anemia management and cancer supportive care. It develops and markets products used to reduce the risk of preterm birth in women with a single baby who have a history …
  • Bone Solutions Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bone Solutions Inc (BSI) is a medical device company that provides orthobiologics technology solutions. The company also develops magnesium oxide based technologies for multitude of orthopedic applications. It provides osteocrete bone graft substitute that offers adhere ligaments and tendons …
  • Satrec Initiative Co., Ltd.:企業の戦略・SWOT・財務分析
    Satrec Initiative Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Satrec Initiative Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Addvalue Technologies Limited (A31):企業の財務・戦略的SWOT分析
    Addvalue Technologies Limited (A31) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Jyoti Structures Ltd (JYOTISTRUC):企業の財務・戦略的SWOT分析
    Jyoti Structures Ltd (JYOTISTRUC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Permian Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Permian Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Permian Basin Royalty Trust (Permian Basin Royalty) is an oil and gas company that owns overriding royalty rights in mineral properties in the US. The company provides oil and gas product …
  • Alitair Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Alitair Pharmaceuticals Inc (Alitair) is a pharmaceutical company that provides orphan drugs and medicine products. The company provides orphan drug products and RX and OTC cough and cold products. It offers orphan drug products such as ALT and oral drugs that are widely used to treat variou …
  • JSR Corporation (4185):企業の財務・戦略的SWOT分析
    JSR Corporation (4185) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Avara Pharmaceutical Services Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Avara Pharmaceutical Services Inc (Avara) is a contract development and manufacturing organization that provides primary formulation and manufacturing, secondary manufacturing and packaging of small molecules. It offers wide range of services such as manufacturing of active pharmaceutical in …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆